CATX — Perspective Therapeutics, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 728387 ·
Last close
$2.66
Market Cap
$303.64M
52W High
$6.16
52W Low
$1.96
ADV30
2,147,637
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -29,258,000 | -26,786,000 | 392,025,000 | 48,488,000 | 68,162,000 |
| Mar 2026 | 0 | — | -28,281,000 | -26,189,000 | 410,769,000 | 53,972,000 | 63,331,000 |
| Dec 2025 | 0 | — | -39,832,000 | -37,490,000 | 266,972,000 | 30,629,000 | 59,941,000 |
| Sep 2025 | 0 | — | -27,861,000 | -25,969,000 | 294,825,000 | 26,762,000 | 52,609,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-92,370,000
Investing CF
$-62,760,000
Financing CF
$164,696,000
CapEx
$-14,951,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.14
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-361,029,000
Inventory
—
Receivables
$58,000
ST Investments
$216,957,000
EBIT TTM
$-112,087,000
Pretax Income TTM
$-112,440,000
Interest Exp TTM
$353,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$409,000
EBITDA
$-121,186,000
Free Cash Flow
$-69,425,624
Enterprise Value
$87,853,176
Total Cash
$236,876,000
Total Debt
$3,963,000
Shares Out
114,151,663
Trailing EPS
$-1.33
Book Value
$2.84
ROE
-39.6%
ROA
-22.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -113,564,000 | -103,121,000 | 266,972,000 | 59,941,000 | 207,031,000 | -82,484,000 |
| Dec 2024 | 0 | -66,797,000 | -79,279,000 | 341,101,000 | 50,433,000 | 290,668,000 | -18,294,000 |
| Dec 2023 | 0 | -40,941,000 | -46,508,000 | 97,891,000 | 22,712,000 | 75,179,000 | -36,913,000 |
| Jun 2022 | 10,795,000 | -7,391,000 | -7,272,000 | 64,439,000 | 3,162,000 | 61,277,000 | -7,710,000 |
TTM Snapshot
Revenues TTM
$7,927,000
NetIncome TTM
$-111,133,000
OpCashFlow TTM
—
Assets (Latest)
$410,769,000
Forward EPS
$-1.02
Max Pain — expiry 2027-01-15
max pain strike: $2.50 · spot: $2.66 · call oi: 6,707 · put oi: 401
Expected Move to 2027-01-15:
±$1.07
(40.41%) —
implied range
$1.59 –
$3.74
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BNTC | Benitec Biopharma Inc. | $304.72M | $8.87 | — |
| CYPH | CYPHERPUNK TECHNOLOGIES INC. | $316.83M | $2.94 | — |
| BIOA | BioAge Labs, Inc. | $290.99M | $6.34 | — |
| FULC | Fulcrum Therapeutics, Inc. | $287.64M | $3.77 | — |
| ABEO | ABEONA THERAPEUTICS INC. | $282.49M | $4.94 | — |
News headlines (Yahoo Finance, 1h cache)
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
2026-10-08 10:16 · Yahoo
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
2026-10-02 15:46 · Yahoo
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
2026-09-14 10:16 · Yahoo
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
2026-09-11 10:00 · Yahoo
Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says
2026-08-11 15:39 · Yahoo
Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
2026-08-04 13:40 · Yahoo
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
2026-07-29 13:55 · Yahoo
Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs
2026-07-28 10:30 · Yahoo
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026
2026-07-17 16:22 · Yahoo
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?
2026-07-16 13:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.